Holding(s) in Company

RNS : FOR IMMEDIATE RELEASE

26 OCTOBER 2016

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.

 

Full disclosure of the TR1 is shown below:

 

-Ends-

For further information please contact:   ImmuPharma plc (www.immupharma.org) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma           + 44 (0) 7721 413496       Panmure, Gordon & Co., (NOMAD & Broker)   +44 (0) 20 7886 2500 Freddy Crossley, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking     Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, John Howes, Corporate Broking                                                                  +44 (0)20 3861 6631

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				x
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	The placement by ImmuPharma PLC of 2,857,143 new ordinary shares			x
3. Full name of person(s) subject to the notification obligation: iii		Lanstead Capital LP
4. Full name of shareholder(s)  (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		21 October 2016
6. Date on which issuer notified:		25 October 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		14%, 13%, 12%, 11%, 10%, 9%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0033711010

17,893,456

17,893,456

10,521,555

10,521,555

8.44%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

N/A

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,521,555

8.44%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
N/A
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:	Lisa De Vargas, Lanstead Partners Limited
15. Contact telephone number:	+1 (801) 895-3700